NCT05639244

Brief Summary

The goal of this cross over study is to investigate the effect of short term time restricted eating (TRE) on the innate immune system in patients with a history of myocardial infarction.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
23

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Nov 2022

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 16, 2022

Completed
1 month until next milestone

Study Start

First participant enrolled

November 17, 2022

Completed
19 days until next milestone

First Posted

Study publicly available on registry

December 6, 2022

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 25, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 25, 2024

Completed
Last Updated

March 27, 2024

Status Verified

November 1, 2023

Enrollment Period

1.2 years

First QC Date

October 16, 2022

Last Update Submit

March 26, 2024

Conditions

Keywords

time restricted eating

Outcome Measures

Primary Outcomes (1)

  • The change in the inflammatory phenotype of circulating immune cells, assessed by measuring the cytokine production capacity (e.g. IL-1b and TNF) of isolated PBMCs after ex vivo stimulation with various TLR ligands, determined by ELISA.

    The investigators will measure the change in the inflammatory phenotype of circulating immune cells after TRE. Therefore, the investigators will assess the inflammatory phenotype at baseline and after a two week TRE period and a control period with a regular diet (cross-over design). This will be assessed by measuring the cytokine production capacity of isolated peripheral blood mononuclear cells (PBMCs) after ex vivo stimulation with various TLR ligands. Relevant cytokines (e.g. IL-1b and TNF, given in pg/ml) are measured in the supernatants of the PMBC stimulation experiments by ELISA.

    Change from baseline cytokine production capacity at 2 weeks after TRE or regular diet.

Study Arms (2)

First TRE, then regular diet

OTHER

This group will start with 2 weeks TRE and will switch to the 2 week period of consuming their regular diet after a wash-out period.

Behavioral: Time restricted eating (TRE)Behavioral: Regular diet

First regular diet, then TRE

OTHER

This group will start with the 2 week period of consuming their regular diet and will switch to 2 weeks TRE after a wash-out period.

Behavioral: Time restricted eating (TRE)Behavioral: Regular diet

Interventions

Participants have to consume their regular food intake during a 6 hour period per day for 2 weeks.

First TRE, then regular dietFirst regular diet, then TRE
Regular dietBEHAVIORAL

Participants have to consume their regular diet within an unrestricted time period for 2 weeks

First TRE, then regular dietFirst regular diet, then TRE

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult (age \>18 years)
  • Diagnosed with a myocardial infarction (between 1 and 5 years ago)
  • Body mass index between 20 and 35 kg/m2
  • Able to understand, be motivated and follow the study related procedures
  • Able to understand and give written informed consent

You may not qualify if:

  • Myocardial infarction (defined as an increase in cardiac enzymes in combination with symptoms of ischemia or newly developed ischemic ECG changes), coronary artery bypass graft surgery or other major (cardiovascular) surgery, stroke or transient ischemic attack (TIA) in the past 1 year prior to screening.
  • Use of immunomodulatory drugs
  • Use of drugs that need to be taken with food.
  • Diabetes Mellitus type I and type II
  • Medical history of any disease associated with immune deficiency (either congenital or acquired, including chemotherapy, active malignancy, organ transplant) or auto immune disease
  • Clinically significant infections within 1 months prior to start of or during intervention period or control period (defined as fever \>38.5).
  • Vaccination \<1 month before start of or during intervention or control period.
  • Eating disorders

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Radboud university medical center

Nijmegen, Gelderland, 6500 GB, Netherlands

Location

MeSH Terms

Conditions

Intermittent FastingMyocardial InfarctionAtherosclerosis

Interventions

Diet

Condition Hierarchy (Ancestors)

FastingFeeding BehaviorBehaviorMyocardial IschemiaHeart DiseasesCardiovascular DiseasesVascular DiseasesInfarctionIschemiaPathologic ProcessesPathological Conditions, Signs and SymptomsNecrosisArteriosclerosisArterial Occlusive Diseases

Intervention Hierarchy (Ancestors)

Nutritional Physiological PhenomenaDiet, Food, and NutritionPhysiological Phenomena

Study Officials

  • Niels P. Riksen, Prof. Dr.

    Radboud University Medical Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
CROSSOVER
Model Details: The investigators will include 20 adult patients. Participants will be randomised to a 2 week time restricted eating (TRE) period or a 2 week period in which they consume their regular diet within an unrestricted time period. Participants will be crossed over to the other treatment arm after a 6 weeks wash-out period.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 16, 2022

First Posted

December 6, 2022

Study Start

November 17, 2022

Primary Completion

January 25, 2024

Study Completion

January 25, 2024

Last Updated

March 27, 2024

Record last verified: 2023-11

Data Sharing

IPD Sharing
Will share

Data will be published in a data repository or other online data archive (e.g. DANS EASY, Radboud Data Repository, disciplinary repository, data archive). Data that is applicable for sharing (regarding privacy) will be published.

Time Frame
All data from the research project will be shared after the publication of the results.
Access Criteria
All data will be made available without restrictions.

Locations